Dr. Ian Anderson, M.D.
Claim this profileProvidence Medical Foundation
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
32 drugs studied
About Ian Anderson, M.D.
Education:
- Obtained an MD from the University of Washington School of Medicine in 2015.
- Completed a residency in Internal Medicine at Providence St. Vincent Medical Center, Portland, Oregon (2015-2018).
- Board Certified in Internal Medicine by the American Board of Internal Medicine.
Experience:
- Practices as an internal medicine physician at Providence Medical Foundation.
Area of expertise
1Lung Cancer
metastatic
Stage IV
locally advanced
2Non-Small Cell Lung Cancer
Stage IV
metastatic
Stage III
Affiliated Hospitals
Clinical Trials Ian Anderson, M.D. is currently running
APL-101
for Lung Cancer
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Recruiting1 award Phase 211 criteria
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
More about Ian Anderson, M.D.
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Ian Anderson, M.D. has experience with
- Pembrolizumab
- Disitamab Vedotin
- Carboplatin
- Gemcitabine
- Cisplatin
- PRO1184
Breakdown of trials Ian Anderson, M.D. has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ian Anderson, M.D. specialize in?
Ian Anderson, M.D. focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved metastatic patients, or patients who are Stage IV.
Is Ian Anderson, M.D. currently recruiting for clinical trials?
Yes, Ian Anderson, M.D. is currently recruiting for 10 clinical trials in Santa Rosa California. If you're interested in participating, you should apply.
Are there any treatments that Ian Anderson, M.D. has studied deeply?
Yes, Ian Anderson, M.D. has studied treatments such as Pembrolizumab, Disitamab Vedotin, Carboplatin.
What is the best way to schedule an appointment with Ian Anderson, M.D.?
Apply for one of the trials that Ian Anderson, M.D. is conducting.
What is the office address of Ian Anderson, M.D.?
The office of Ian Anderson, M.D. is located at: Providence Medical Foundation, Santa Rosa, California 95403 United States. This is the address for their practice at the Providence Medical Foundation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.